Private equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as well [Yahoo! Finance]
Kinnate Biopharma Inc. (KNTE)
Company Research
Source: Yahoo! Finance
A total of 3 investors have a majority stake in the company with 51% ownership Institutions own 31% of Kinnate Biopharma To get a sense of who is truly in control of Kinnate Biopharma Inc. ( NASDAQ:KNTE ), it is important to understand the ownership structure of the business. We can see that private equity firms own the lion's share in the company with 45% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Following a 11% increase in the stock price last week, private equity firms profited the most, but institutions who own 31% stock also stood to gain from the increase. In the chart below, we zoom in on the different ownership groups of Kinnate Biopharma. Check out our latest analysis for Kinnate Biopharma What Does The Institutional Ownership Tell Us About Kinnate Biopharma? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are
Show less
Read more
Impact Snapshot
Event Time:
KNTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNTE alerts
High impacting Kinnate Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
KNTE
News
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, DOOR, HMSTGlobeNewswire
- KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEBusiness Wire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - EVBG, TAST, ZFOX, KNTEPR Newswire
- XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]Yahoo! Finance
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - KNTE, INBX, KAMNAccesswire
KNTE
Earnings
- 11/9/23 - Beat
KNTE
Sec Filings
- 4/3/24 - Form S-8
- 4/3/24 - Form S-8
- 4/3/24 - Form S-8
- KNTE's page on the SEC website